极速25天！特应性皮炎新药达必妥®创生物制剂上市最快速度

参考文献：

[1] CY HWANG, et al. Prevalence of Atopic Dermatitis, Allergic Rhinitis and Asthma in Taiwan: A National Study 2000 to 2007. Acta Derm Venereol 2010; 90: 589–594

[2] YS Yu, et al. Prevalence of atopic dermatitis in Korea: analysis by using national statistics. J Korean Med Sci. 2012; 27(6): 681–685.

[3] S. Barbarot, et al. Epidemiology of atopic dermatitis in adults: Results from an international survey.  2018, Allergy, 2018, 73 (6): 1284-1293.

[4] Simpson E L, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis[J]. New England Journal of Medicine, 2016, 375(24): 2335-2348.

[5] Silverberg J I, Yosipovitch G, Simpson E L, et al. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate-to-severe atopic dermatitis: analysis of the randomized phase 3 studies SOLO 1 & SOLO 2, AD ADOL, and CHRONOS[J]. Journal of the American Academy of Dermatology, 2020.

[6] Blauvelt, Andrew, et al. "Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial." The Lancet 389.10086 (2017): 2287-2303.

[7] de Bruin‐Weller, M., et al. "Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo‐controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ)." British Journal of Dermatology 178.5 (2018): 1083-1101.